spacer
home > white papers > Autoinjectors From Planning to Launch - SHL Group
WHITE PAPERS
logo_SHL_Groupl.jpg

SHL Group

phone +886 3 217 0303
email info@shl-group.com
web http://www.shl-group.com/
email No.136 Kuo Sheng 2nd Street, Taoyuan, Taiwan 330

Autoinjectors From Planning to Launch

Looking at the rising trend towards self-administration therapies, injectable drug delivery devices such as pen injectors, autoinjectors and needle free injectors show a significant growth potential in the near future. In 2010, the pen systems and autoinjectors market was estimated to be worth over $0.58bn, a growth of 8-10% from previous years. It is estimated that the market will continue to grow steadily between 10-15% over the forecast period. It will reach $0.87bn in 2013 and $1.07bn in 2015. (Visiongain, June, 2011)
Autoinjectors From Planning to Launch
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>


White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>


Industry Events

Clinical Trial Supply East coast 2018

16-17 October 2018, King of Prussia, PA

This unique event brings together leading pharma, device and biotech professionals from across the East Coast region, to collaboratively enhance the clinical supply chain. Over the two days, delegates and speakers will discuss how to select forecasting and planning technology, how to reduce waste in clinical trials supplies, how to choose your packaging strategy, but we will also discover all the new technologies that will disrupt your clinical trials supplies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement